What We're Reading: Page 181
Industry reads hand-picked by our editors
Sep 28, 2020
Sep 25, 2020
-
The New York Times
New York Will Review Virus Vaccines, Citing Politicization of Process
-
The Wall Street Journal
A Bet on Europe Is a Bet on Drugs, Against Tech
-
Bloomberg
Opioid Distributors Get ‘Negotiation Class’ Tossed on Appeal
-
BioCentury
Gilead’s bid for Immunomedics exceeded rival offer by nearly $8B
Sep 24, 2020
Sep 23, 2020
-
The Wall Street Journal
Draft Guidelines Say Covid-19 Vaccine to Require Strict Review for Authorization
-
STAT
MIT researcher held up as model of how algorithms can benefit humanity
-
The New York Times
Coronavirus Vaccine Trials Could Suffer From Shortcuts
-
FiercePharma
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Sep 22, 2020
Sep 21, 2020
-
BioCentury
Controversy over Azar memo highlights concerns about politicization of FDA
-
The New York Times
A Deal on Drug Prices Undone by White House Insistence on ‘Trump Cards'
-
STAT
Black doctors' group creates panel to vet Covid-19 vaccines
-
Evaluate Vantage
Esmo 2020 puts Opdivo and Cabometyx back in the game
Previous
